Get all your news in one place.
100’s of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
Health
Ella Pickover

Hot flush pill for menopausal women approved for use in UK

Women in the UK will soon have access to a new daily pill designed to alleviate hot flushes during menopause, following its approval for use.

The Medicines and Healthcare products Regulatory Agency (MHRA) has become the first global regulator to give the green light to elinzanetant, also known as Lynkuet.

Developed by Bayer, this treatment offers an alternative to hormone replacement therapy (HRT) for those experiencing vasomotor symptoms, commonly known as hot flushes.

HRT is currently a widely used option for managing various menopause and perimenopause symptoms, including these disruptive flushes.

But not all patients want or are able to take hormone treatments.

At present elinzanetant is not available on the NHS but the green light from the MHRA means that it can be purchased privately in the UK.

Menopause and perimenopause can cause symptoms including hot flushes. (Getty Images)

It is to be considered by the NHS spending watchdog, the National Institute for Health and Care Excellence.

Hot flushes and night sweats are one of the most common symptoms of menopause.

It is understood that as oestrogen levels decline around menopause, the body’s temperature regulation system can be disrupted when certain brain cells become overactive.

The new treatment, which is a non-hormonal medication, works by calming these signals in the brain.

Clinical trial data showed that the drug was safe and well tolerated and reduced hot flushes compared with a dummy drug, also known as a placebo.

It was also linked to fewer sleep disturbances and women taking it reported a better quality of life compared with those taking the placebo.

“Hot flushes and night sweats associated with menopause can have a significant negative impact on quality of life,” said Julian Beach, the MHRA’s interim executive director of healthcare quality and access.

“We are therefore pleased to announce our approval of elinzanetant, which has met the MHRA’s standards for safety, quality and effectiveness.

“Elinzanetant offers a non-hormonal alternative for those who may not be able to, or prefer not to, take hormone-based therapies.

“As with all licensed medicines, we will continue to monitor its safety closely as it becomes more widely used.”

Women usually go through the menopause when they are aged between 45 and 55, though it can start sooner.

During the menopause a woman’s periods stop due to lower hormone levels.

Menopause and perimenopause can cause symptoms including anxiety, mood swings, brain fog, hot flushes and irregular periods.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.